Wealth Enhancement Advisory Services
SAGE

Wealth Enhancement Advisory Services’s Sage Therapeutics SAGE Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-34,046
Closed -$313K – 3684
2025
Q2 		$313K Sell
34,046
-9,592
-22% -$70.5K ﹤0.01% 2601
2025
Q1 		$347K Buy
+43,638
New +$320K ﹤0.01% 2327

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Wealth Enhancement Advisory Services's SAGE Position: Q3 2025 in Review

Wealth Enhancement Advisory Services sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 34,046 shares — an estimated $313K sold.

Wealth Enhancement Advisory Services first reported a position in SAGE in Q1 2025 and held it in 2 quarters. The position peaked at $347K in Q1 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Wealth Enhancement Advisory Services reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 34,046 Sage Therapeutics shares in Q3 2025, an estimated $313K.
  • Wealth Enhancement Advisory Services first reported a position in Sage Therapeutics in Q1 2025 and held it in 2 quarters.
  • Wealth Enhancement Advisory Services's Sage Therapeutics position peaked at $347K in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2025, filed 29 Oct 2025.